Eliasson E - Search Results

1

Serum levels of 25-hydroxyvitamin D and the CYP3A biomarker 4β-hydroxycholesterol in a high-dose vitamin D supplementation study.

Björkhem-Bergman L, Nylén H, Norlin AC, Lindh JD, Ekström L, Eliasson E, Bergman P, Diczfalusy U. Björkhem-Bergman L, et al. Among authors: eliasson e. Drug Metab Dispos. 2013 Apr;41(4):704-8. doi: 10.1124/dmd.113.051136. Epub 2013 Feb 5. Drug Metab Dispos. 2013. PMID: 23386704 Clinical Trial.

2

Seasonal variation in blood drug concentrations and a potential relationship to vitamin D.

Lindh JD, Andersson ML, Eliasson E, Björkhem-Bergman L. Lindh JD, et al. Among authors: eliasson e. Drug Metab Dispos. 2011 May;39(5):933-7. doi: 10.1124/dmd.111.038125. Epub 2011 Feb 24. Drug Metab Dispos. 2011. PMID: 21349923

3

Vitamin D and drug-metabolising enzymes.

Lindh JD, Björkhem-Bergman L, Eliasson E. Lindh JD, et al. Among authors: eliasson e. Photochem Photobiol Sci. 2012 Dec;11(12):1797-801. doi: 10.1039/c2pp25194a. Photochem Photobiol Sci. 2012. PMID: 22903070

4

Plasma levels of 25-hydroxyvitamin D3 and in vivo markers of cytochrome P450 3A activity in Swedes and Koreans: effects of a genetic polymorphism and oral contraceptives.

Nylén H, Björkhem-Bergman L, Ekström L, Roh HK, Bertilsson L, Eliasson E, Lindh JD, Diczfalusy U. Nylén H, et al. Among authors: eliasson e. Basic Clin Pharmacol Toxicol. 2014 Oct;115(4):366-71. doi: 10.1111/bcpt.12230. Epub 2014 Apr 11. Basic Clin Pharmacol Toxicol. 2014. PMID: 24655660 Free article.

5

A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele.

Andersson ML, Eliasson E, Lindh JD. Andersson ML, et al. Among authors: eliasson e. Pharmacogenomics. 2012 May;13(7):757-62. doi: 10.2217/pgs.12.40. Pharmacogenomics. 2012. PMID: 22594507

6

Influence of simvastatin on the thromboxane and prostacyclin pathways, in vitro and in vivo.

Skogastierna C, Björkhem-Bergman L, Bergman P, Eliasson E, Rane A, Ekström L. Skogastierna C, et al. Among authors: eliasson e. J Cardiovasc Pharmacol. 2013 Jan;61(1):1-7. doi: 10.1097/FJC.0b013e3182734508. J Cardiovasc Pharmacol. 2013. PMID: 22987053

7

CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients.

Margolin S, Lindh JD, Thorén L, Xie H, Koukel L, Dahl ML, Eliasson E. Margolin S, et al. Among authors: eliasson e. Pharmacogenomics. 2013 Apr;14(6):613-22. doi: 10.2217/pgs.13.47. Pharmacogenomics. 2013. PMID: 23570465

8

Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles.

Thorén L, Lindh JD, Ackehed G, Kringen MK, Hall P, Bergh J, Molden E, Margolin S, Eliasson E. Thorén L, et al. Among authors: eliasson e. Br J Clin Pharmacol. 2021 Mar;87(3):1243-1252. doi: 10.1111/bcp.14500. Epub 2020 Aug 9. Br J Clin Pharmacol. 2021. PMID: 32713032 Free PMC article.

9

Bleeding and thromboembolism due to drug-drug interactions with non-vitamin K antagonist oral anticoagulants-a Swedish, register-based cohort study in atrial fibrillation outpatients.

Holm J, Mannheimer B, Malmström RE, Eliasson E, Lindh JD. Holm J, et al. Among authors: eliasson e. Eur J Clin Pharmacol. 2021 Mar;77(3):409-419. doi: 10.1007/s00228-020-03015-7. Epub 2020 Oct 7. Eur J Clin Pharmacol. 2021. PMID: 33029651 Free PMC article.

10

Therapeutic drug monitoring for tomorrow.

Eliasson E, Lindh JD, Malmström RE, Beck O, Dahl ML. Eliasson E, et al. Eur J Clin Pharmacol. 2013 May;69 Suppl 1:25-32. doi: 10.1007/s00228-013-1504-x. Epub 2013 May 3. Eur J Clin Pharmacol. 2013. PMID: 23640185 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

144 results

Search Page

Filters